Skip to content
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT

Press & Updates

Here you will find updates on our work at Albert Labs.
Keep up to date with our progress by following us on social media.
Twitter
Linkedin
Youtube
Instagram
Albert Labs Announces Private Placement@4x
Ingenu LOI@4x
Corporate Update@4x
Albert Labs PCT Patent@4x
industry leading directors
real world evidence principal investigator
Health Canada Licence psilocybin psychoactive
pre-clinical toxicological research CESPU
scientific advisory board toxicology
Patent
Canadian Securities Exchange
MHRA Real World Evidence Data

Corporate Updates

Albert Labs Announces Private Placement@4x
Ingenu LOI@4x
Corporate Update@4x
Albert Labs PCT Patent@4x
industry leading directors
real world evidence principal investigator
Health Canada Licence psilocybin psychoactive
pre-clinical toxicological research CESPU
scientific advisory board toxicology
Patent
Canadian Securities Exchange
MHRA Real World Evidence Data
Previous
Next

In the News

News

Health Canada Psychedelic Medicine
  • May 24, 2022
  • Microdose

Health Canada Continues to Support Psychedelic Medicine

Freddie Earlam

News

Magic Mushroom Medicine
  • May 20, 2022
  • CTV News

Burnaby company granted Health Canada licence to produce ‘magic mushroom medicine’

Kevin Charach

News

psilocybin cancer patients UK
  • April 25, 2022
  • Filter

The Mission to Make Psilocybin Available to UK Cancer Patients

Kiran Sidhu

Interviews

imperial college psilocybin depression Real-World Evidence
  • April 14, 2022

Imperial College study on psilocybin for depression highlights need for Real-World Evidence trials

News

UK research centre psychedelic medicine
  • March 15, 2022
  • Microdose

Is the UK Becoming a Global Center for Psychedelic Medicine?

Freddie Earlam

News

Psilocybin Real-World Evidence and the Mental Health Crisis
  • February 9, 2022
  • Truffle Report

Using Real-World Evidence to Accelerate Psychedelic Drug Development

Emily Jarvie

News

CSE Listing
  • November 30, 2021
  • Psychedelic Health

Albert Labs receives conditional approval for CSE listing

Stephanie Price

News

Psychedelics Company Goes Public
  • November 29, 2021
  • Benzinga

Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker

Javier Hasse

Previous
Next

Industry News

Industry News

psychedelic therapy
  • October 22, 2022
  • The Manual

Psychedelic Therapy isn’t Fringe Anymore

Nick Hilden

Industry News

psychedelics cure
  • October 22, 2022
  • NOVA

Can Psychedelics Cure?

Larkin McPhee

Industry News

discrimination in mental health
  • October 22, 2022
  • The Lancet

The Lancet Commission on Ending Stigma and Discrimination in Mental Health

Prof Graham Thornicroft PhD, Charlene Sunkel NSC, et al.

Industry News

Innovation Passport
  • October 12, 2022
  • PSYCH

The MHRA’s Innovation Passport

Industry News

pharmaceutical dependence
  • October 12, 2022
  • Vogue

Can Psilocybin Challenge Our Pharmaceutical Dependence?

Fiorella Valdesolo

Industry News

magic mushroom experience
  • October 10, 2022
  • Monash University

The Magic Mushroom Experience: Taking Psilocybin for Science

Devon Stoliker, Adeel Razi

Industry News

chronic pain
  • September 28, 2022
  • Nature

The Psychedelic Remedy for Chronic Pain

Clare Watson

Industry News

anxiety distress cancer
  • September 27, 2022
  • The Economist

Psychedelic Therapy could reduce Anxiety, Distress among Patients with Cancer

Alok Jha

Previous
Next

Innovative mental health medicines for patients with unmet needs

  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy

© 2022 Albert Labs. All Rights Reserved

  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Twitter Linkedin Youtube Envelope
CSE:ABRT
FSE: VB50
CSE:ABRT
FSE: VB50

About Albert Labs

We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

If you would like support or more information around making an investment, please contact investing@albertlabs.com

Twitter Linkedin Youtube Envelope

Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

Twitter
Youtube
Linkedin
Instagram
Envelope
Twitter
Youtube
Linkedin
Instagram
Envelope

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok